Biogennix’s DirectCell advanced bone grafting system used in 500th case

1214
DirectCell system (Biogennix)

Biogennix has announced that its DirectCell advanced bone grafting system has now been used in more than 500 cases.

The DirectCell system includes a bone graft product with advanced bone regeneration properties along with novel instrumentation engineered to harvest high concentrations of patient stem cells, say Biogennix.

The cell-stimulating graft within the system is the advanced synthetic bone graft, Agilon, which is available in a mouldable and strip form. Agilon products are based on Biogennix’s TrelCor technology that contains a nanocrystalline hydroxycarbanoapatite graft surface which actively participates in bone regeneration.

The DirectCell system also provides surgeons two methods of collecting bone marrow derived stem cells, either through the harvesting of stem cell aspirate with significantly higher stem cell counts (compared to standard bone marrow aspirate) or marrow-rich autograft dowels.

“The DirectCell System provides surgeons the means to harvest tissue with high stem cell counts and combine it with a graft material that is actively involved in the cellular bone formation response­­”, said Mark Borden, Biogennix’s CTO. “This results in an optimal biological graft that immediately begins the bone regeneration process.”

Jeffrey Wang, chief of orthopaedic spine service at USC and co-director of the USC Spine Center (Los Angeles, USA), has been he using the product in his spine fusion cases. He commented: “When you combine live cells with an advanced surface, you are optimising the healing response. Surgeons and hospitals alike need innovative solutions with strong scientific backing, which incorporate new biological technologies.”

Biogennix CEO Chris MacDuff, added: “As a company our strength has always been our focus and deep expertise in advanced bone regeneration technologies. I attribute the swift success of the DirectCell system primarily to the solid science supporting its benefits.

“When you use the patient’s own cells, you completely eliminate the risk of disease transmission that has recently been seen with cadaver-based stem cell products. The DirectCell system not only enables the harvest of significantly higher cell counts, but it is a safer and significantly more cost-effective alternative.”

 


LEAVE A REPLY

Please enter your comment!
Please enter your name here